Esperion Therapeutics, Inc (NASDAQ:ESPR) Receives Consensus Rating of Hold from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
(Family Features) Heart disease is the nation’s leading cause of death for men and women, according to the Centers for Disease Control and Prevention, but many people aren’t aware they
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $16.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $2.50 EPS, FY2027 earnings at […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) was the recipient of some unusual options trading on Monday. Investors acquired 11,472 call options on the stock. This represents an increase of approximately 223% compared to the average daily volume of 3,554 call options. Wall Street Analyst Weigh In ESPR has been the subject of several […]